Emil Lou, Professor with Tenure at the University of Minnesota, shared a post on LinkedIn:
“RAS RAS RAS … and more RAS
That is what will be on the tip of everyone’s tongues at ASCO26 and beyond.
This discussion was half a century in the making, from the discovery of the RAS oncogene, all the way to long-awaited advances in targeting this previously elusive cancer target.
Here’s my commentary in Medscape, posted May 14, 2026:
The Rise of Pan-RAS Inhibitors in Pancreatic Cancer”
Other articles featuring Emil Lou on OncoDaily.